These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15837769)

  • 1. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
    Zhang X; Li W; Olumi AF
    Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
    Mori E; Thomas M; Motoki K; Kataika S
    FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
    Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
    Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
    Zhang L; Zhang X; Barrisford GW; Olumi AF
    Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
    Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
    Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2.
    Mori E; Thomas M; Motoki K; Nakazawa K; Tahara T; Tomizuka K; Ishida I; Kataoka S
    Cell Death Differ; 2004 Feb; 11(2):203-7. PubMed ID: 14576771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.